Benign Enlargement

Slide 1 · Benign Enlargement

Benign prostatic hyperplasia

Mechanisms · Morphology · Clinicopathologic consequences

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Define BPH and distinguish histologic hyperplasia from malignancy.

Explain DHT, androgen-receptor and growth-factor mechanisms.

Recognize gross and microscopic patterns and consequences of obstruction.

Connect medical and procedural treatment to pathophysiology.

Slide 3 · What benign prostatic enlargement means

BPH is a nodular increase in prostatic stromal and glandular tissue.

The lesion is benign; Expansion can still impair urinary outflow.

The central clinical relationship is transition-zone growth around the urethra.

Stromal + glandular proliferation

Transition-zone nodules

Urethral compression

Slide 4 · Hyperplasia is the appropriate morphologic term

Hyperplasia refers to increased cell number within glandular and stromal components.

The textbook also mentions the traditional term “benign prostatic hypertrophy.”

“Nodular hyperplasia” describes the characteristic growth pattern.

Hyperplasia

Hypertrophy

Cell-number increase

Cell-size increase

Glandular + stromal

Not the preferred label for BPH

Slide 5 · BPH does not represent a premalignant lesion

The benign epithelial and stromal proliferation does not define a cancer precursor.

Do not infer malignant progression from nodular enlargement alone.

The prostate also develops carcinomas, but their zonal predilection differs.

BPH

Prostatic carcinoma

Benign nodules

Malignant neoplasm

Transition-zone predilection

Peripheral-zone predilection

Slide 6 · BPH is a common disorder of aging

BPH as the most common benign prostatic disease after age 50.

Its burden should be described separately as histologic prevalence and symptomatic disease.

Age-associated frequency does not make clinically significant obstruction harmless.

~30%

Symptomatic BPH

American males of European descent >50 y

Moderate-to-severe symptoms

Up to 90%

Histologic BPH

Males by age 80 y

Histologic evidence

Different measures and populations — not directly interchangeable

Slide 7 · Interpret epidemiologic figures carefully

Approximately 30% applies to moderate-to-severe symptoms in a specified American ancestry group older than 50.

Up to 90% by age 80 refers to histologic evidence, not the same symptomatic endpoint.

These textbook observations cannot be treated as universal population estimates.

Clinical symptoms

Histologic evidence

Patient-reported disease burden

Tissue-based microscopic finding

Population qualification matters

Different denominator and endpoint

Slide 8 · The adult prostate: Glands in fibromuscular stroma

The normal organ surrounds the proximal urethra and weighs about 20 g.

Glands reside within abundant fibromuscular stroma.

Both cellular compartments are implicated in BPH.

Luminal space

Secretory epithelium

Basal layer

Schematic glands; Diagnostic features require genuine H&E review

Slide 9 · Prostatic zones are biologically distinct

The chapter distinguishes peripheral, central, transition, and periurethral regions.

Their differing lesion distributions provide diagnostic context.

BPH predominantly affects the transition and inner periurethral regions.

Peripheral region

Transition region

Prostatic urethra

Slide 10 · Transition-zone position explains obstruction

The transition zone lies close to the prostatic urethra.

Expanding nodules can reduce the lumen even without malignant invasion.

Clinical impact depends on both tissue bulk and associated smooth-muscle tone.

Peripheral region

Transition-zone nodules

Prostatic urethra

Slide 11 · BPH and adenocarcinoma: Distinct usual origins

The textbook places most hyperplasia in the transition zone.

Most adenocarcinomas are instead described as arising in the peripheral zone.

This is an anatomic distinction, not a method for excluding coexisting pathology.

BPH

Adenocarcinoma

Transition / periurethral

Predominantly peripheral

Benign stromal + glandular nodules

Malignant epithelial tumor

Slide 12 · The normal gland contains two epithelial layers

An inner columnar secretory layer lines the glandular lumen.

An outer layer of basal cells is cuboidal or flattened.

Recognition of both layers is important when describing benign glandular structures.

Luminal space

Secretory epithelium

Basal layer

Schematic glands; Diagnostic features require genuine H&E review

Slide 13 · Prostatic maintenance is androgen dependent

Testicular androgens regulate prostatic cell growth and survival.

The parent chapter describes epithelial apoptosis and glandular atrophy after castration.

BPH therefore arises in a hormonally responsive tissue compartment.

Testicular androgen supply

Prostatic androgen signaling

Epithelial growth and survival

Slide 14 · Overview: Prostatic hyperplasia is multifactorial

DHT provides a dominant androgen signal.

Androgen-responsive growth factors connect stromal and epithelial compartments.

Estrogen-related pathways further favor a net increase in tissue mass.

Androgenic + estrogenic influences

Cell proliferation increases

Epithelial cell death decreases

Benign nodular growth

Slide 15 · Testosterone supplies the substrate for DHT

Testosterone reaches the prostate and undergoes local metabolic conversion.

Dihydrotestosterone (DHT) is the principal intraprostatic androgen emphasized by Robbins.

This conversion provides a therapeutic target rather than merely a circulating hormone measurement.

Testosterone

5α-reductase conversion

Dihydrotestosterone

Slide 16 · Type 2 5α-reductase is predominantly stromal

The chapter localizes type 2 5α-reductase primarily to stromal cells.

It specifies that type 2 enzyme is not expressed in prostatic epithelial cells.

The stroma is therefore a major site of local DHT generation.

Testosterone enters prostate

Type 2 5α-reductase in stroma

Locally generated DHT

Slide 17 · Extraprostatic tissues also generate DHT

Type 1 5α-reductase contributes to testosterone conversion in the liver and skin.

The resulting DHT can reach the prostate via the circulation.

BPH hormone exposure includes both local and extraprostatic sources.

Testosterone

Prostate: Type 2 enzyme

Skin/liver: Type 1 enzyme

DHT available to prostate

Slide 18 · DHT has more sustained receptor binding

DHT binds androgen receptors with greater affinity than testosterone.

Its androgen receptor complex is more stable.

Greater receptor affinity explains why it is a potent intraprostatic androgen signal.

Testosterone–AR

DHT–AR

Lower relative affinity

Higher relative affinity

Less stable complex

More stable complex

Slide 19 · Androgen receptors occur in both compartments

Stromal cells contain androgen receptors.

Prostatic epithelial cells also contain androgen receptors.

DHT therefore influences a coupled stromal–epithelial tissue system.

DHT

AR in stromal cells

AR in epithelial cells

Compartment-specific responses

Slide 20 · Androgen receptor activation is nuclear

DHT binding activates cytoplasmic androgen receptors.

The activated receptors translocate to the nucleus.

Nuclear AR signaling regulates transcription of androgen-dependent genes.

DHT binds cytoplasmic AR

Activated AR enters nucleus

Androgen-responsive gene transcription

Slide 21 · Androgen-dependent genes alter growth signaling

AR target genes include growth factors and their receptors.

Fibroblast growth factor (FGF) and transforming growth factor-β (TGF-β).

The growth response is mediated indirectly as well as through receptor activation.

Nuclear androgen receptor

Growth-factor / receptor gene expression

Altered stromal–epithelial balance

Slide 22 · Stromal FGFs provide paracrine signaling

FGF-family ligands are produced by stromal cells.

Their paracrine effects support androgen-stimulated epithelial growth.

Stromal–epithelial communication is central to the pathogenesis model.

DHT-stimulated stromal cells

FGF-family growth factors

Adjacent epithelial response

Slide 23 · BPH may reactivate developmental programs

FGF pathways regulate epithelial growth during embryonic prostate development.

The textbook proposes partial reawakening of these pathways during adulthood.

This is a proposed mechanism rather than a proven complete causal explanation.

Development

Adult BPH

FGF-regulated organ growth

Potential pathway reactivation

Physiologic embryonic program

Pathologic nodular enlargement

Slide 24 · TGF-β effects differ by target cell

TGF-β stimulates fibroblasts and other mesenchymal cells.

The same factor can inhibit epithelial proliferation.

Its effects must not be summarized as uniformly pro-proliferative.

Stromal / mesenchymal

Epithelial

TGF-β: Mitogenic action

TGF-β: Proliferation inhibition

Cell-specific response

Different target-cell response

Slide 25 · Hyperplasia reflects a proliferation–death imbalance

Increased proliferation of stromal cells.

Reduced epithelial cell death also contributes to tissue expansion.

Net growth is not equivalent to unchecked epithelial mitosis alone.

↑ stromal proliferation

↓ epithelial cell death

Net accumulation of prostatic tissue

Schematic — qualitative balance; No numerical effect size implied

Slide 26 · Stromal growth is not a secondary afterthought

BPH is histologically a mixed stromal and glandular process.

Androgen metabolism, FGF production, and mesenchymal proliferation all involve stroma.

The fibromuscular component contributes to gland size and obstruction.

Stromal androgen response

Growth-factor and mesenchymal effects

Fibromuscular expansion

Slide 27 · Epithelial accumulation includes enhanced survival

A decrease in epithelial cell death increases epithelial mass over time.

This can occur alongside stromal proliferative activity.

Altered cell turnover as part of the integrated BPH mechanism.

Stromal expansion

Epithelial survival

Glandular + stromal hyperplasia

Schematic — qualitative balance; No numerical effect size implied

Slide 28 · Androgens are permissive, not the whole cause

Androgen availability is required for the characteristic prostatic growth response.

The ultimate initiating cause of BPH remains unknown.

Additional estrogen-dependent and tissue-regulatory mechanisms are implicated.

Prostatic hormonal milieu

Androgen receptor activity

Estrogen-related pathways

Proliferation / survival shift

Slide 29 · Estrogens participate in the growth balance

The chapter cites multiple lines of evidence for estrogen involvement.

Estrogen effects may favor proliferation over cell death.

Their role is best viewed as contributory and mechanistically complex.

Estrogen-linked signaling

Cell-type-specific responses

Shift toward prostatic growth

Slide 30 · Estrogen receptors have opposing effects

ERα is associated with pro-proliferative effects in the source model.

ERβ is associated with antiproliferative effects.

A single undifferentiated “estrogen effect” obscures receptor subtype biology.

ERα

ERβ

Proliferative effect

Antiproliferative effect

Receptor-specific pathway

Opposing receptor activity

Slide 31 · Aromatase and PGE₂ are implicated pathways

Estrogen actions with aromatase expression.

Paracrine regulation involving prostaglandin E₂ also appears in the model.

These associations do not establish a quantitative contribution for either pathway.

Aromatase / estrogen milieu

Paracrine PGE₂-linked regulation

Modulation of tissue growth balance

Slide 32 · Integrated model: Hormones to nodules

DHT–AR signaling modifies growth-factor expression.

FGF and TGF-β actions vary between stromal and epithelial targets.

Estrogen pathways contribute to cell turnover favoring enlargement.

DHT / AR + estrogen pathways

Stromal and epithelial regulation

More prostatic tissue

Nodular transition-zone enlargement

Slide 33 · Grossly, BPH can markedly increase gland weight

The normal prostate is described as weighing roughly 20 g.

BPH commonly produces a three- to fivefold increase, approximately 60–100 g.

Even greater enlargement can occur; Gland weight is not itself a cancer criterion.

Normal prostate

BPH enlargement

Approximately 20 g

Often 60–100 g

Parent chapter baseline

Sometimes larger

Slide 34 · Hyperplastic nodules cluster near the urethra

BPH affects transition-zone and inner periurethral tissue.

Well-defined nodules can project inward as they expand.

The urethral channel may become visibly constricted.

Peripheral region

Transition-zone nodules

Prostatic urethra

Slide 35 · Prostatic urethral narrowing can be slit-like

Large transition-zone nodules can compress the prostatic urethra.

A slit-like urethral orifice in affected glands.

Lumen narrowing is the structural counterpart of the obstructive component.

Bladder

Narrowed outflow

Schematic — bladder and prostatic outlet; Not anatomical scale

Slide 36 · Nodular heterogeneity has a tissue basis

The gross character of a BPH nodule varies with its cellular composition.

Gland-predominant nodules appear and feel different from stromal-predominant ones.

Sampling can therefore show a mixture of distinct tissue patterns.

Gland-predominant

Stroma-predominant

Yellow-pink; Soft

Pale-gray; Firm

Milky secretions possible

Fibromuscular-rich

Slide 37 · Gland-rich nodules are soft and secretory

Gland-predominant nodules are described as yellow-pink and relatively soft.

They may release a milky-white prostatic fluid when cut.

These are gross morphology correlations, not standalone diagnostic criteria.

Luminal space

Secretory epithelium

Basal layer

Schematic glands; Diagnostic features require genuine H&E review

Slide 38 · Stroma-rich nodules are firm

Fibromuscular nodules are pale-gray and firm.

Greater stromal abundance explains their different gross consistency.

BPH remains a mixed epithelial–stromal proliferative process overall.

Glandular tissue

Fibromuscular stroma

Secretory spaces

Spindle-cell tissue

Softer yellow-pink nodules

Firmer pale-gray nodules

Slide 39 · Microscopic nodules mix glands and stroma

Small, medium, and enlarged glands appear within nodules.

They are separated by bland spindle-shaped stromal cells.

Architectural variability is compatible with benign nodular hyperplasia.

Luminal space

Secretory epithelium

Basal layer

Schematic glands; Diagnostic features require genuine H&E review

Slide 40 · Glands often show variable luminal dilation

Hyperplastic glands can range from small to cystically dilated.

The lumen is enclosed by preserved epithelial layers in typical BPH glands.

Variable gland caliber contributes to the heterogeneous microscopic pattern.

Luminal space

Secretory epithelium

Basal layer

Schematic glands; Diagnostic features require genuine H&E review

Slide 41 · Two-layered benign epithelium persists

An inner columnar secretory layer remains identifiable.

An outer cuboidal or flattened basal epithelial layer is present.

Preserved layered architecture is an important benign histologic feature.

Luminal space

Secretory epithelium

Basal layer

Schematic glands; Diagnostic features require genuine H&E review

Slide 42 · Secretory infoldings may simulate papillae

Luminal secretory epithelium can form inward folds.

The resulting papillary architecture is described as a feature of BPH nodules.

Interpret papillary folds in the context of the glandular and stromal background.

Luminal space

Secretory epithelium

Basal layer

Schematic glands; Diagnostic features require genuine H&E review

Slide 43 · Bland stromal spindle cells separate glands

Stromal elements are fibromuscular and spindle shaped.

Nodules can be stromal dominant or gland dominant.

The stromal component should be described rather than ignored during morphology review.

Luminal space

Secretory epithelium

Basal layer

Schematic glands; Diagnostic features require genuine H&E review

Slide 44 · Severe enlargement may compromise perfusion

In very enlarged glands, vascular supply can be insufficient.

Prostatic infarcts may develop in this setting.

Infarction is a secondary effect of marked enlargement, not a necessary BPH finding.

Marked prostatic enlargement

Compromised local blood supply

Possible prostatic infarction

Slide 45 · Squamous metaplasia can occur near infarction

Squamous metaplasia adjacent to areas of prostatic infarction.

This is a reactive epithelial change occurring in a specific setting.

Its presence should be contextualized by the associated tissue injury.

Enlargement with infarction

Adjacent tissue injury

Possible squamous metaplasia

Slide 46 · Morphology synthesis: What to recognize

Nodular enlargement centered on transition/periurethral regions.

Variable glands with two epithelial layers and secretory folds.

Bland spindle-cell stroma, with occasional infarction-related changes.

Gross morphology

Microscopy

Central nodules

Two-layered variable glands

Urethral compression

Fibromuscular stroma

Slide 47 · Two mechanisms increase urinary outflow resistance

Anatomic enlargement reduces the available urethral lumen.

Stromal smooth muscle contraction adds a dynamic resistance component.

Both mechanisms explain why tissue size is not the only treatment target.

BPH at bladder outlet

Tissue bulk / compression

Smooth-muscle contraction

Increased outflow resistance

Slide 48 · The bladder works against greater resistance

Obstruction increases pressure required to empty the bladder.

Bladder muscular-wall hypertrophy and distention.

Functional changes downstream reflect chronic difficulty with urinary outflow.

Prostatic outflow resistance

Bladder muscular-wall response

Hypertrophy and distention

Slide 49 · Incomplete emptying leaves residual urine

Obstructed voiding may prevent complete bladder emptying.

Retained urine remains after micturition.

A persistently residual pool increases the opportunity for infection.

Bladder

Narrowed outflow

Schematic — bladder and prostatic outlet; Not anatomical scale

Slide 50 · Stasis links obstruction to infection

Residual urine is a common reservoir for bacterial growth.

Bacterial infection of the bladder and kidney.

Recurrent urinary infection can therefore be a downstream consequence of BPH.

Outlet obstruction

Incomplete bladder emptying

Residual urinary pool

Predisposition to urinary infection

Slide 51 · Voiding symptoms reflect outlet narrowing

Difficulty initiating the stream reflects increased resistance.

Difficulty stopping and restarting flow is part of the textbook symptom list.

Flow disturbance is a functional manifestation of outlet obstruction.

Reduced urethral lumen + tone

Impaired urine passage

Hesitancy / interrupted voiding

Slide 52 · Frequency and nocturia are common presentations

Increased urinary frequency is included among major symptoms.

Nocturia denotes nighttime need to urinate.

The presence of storage complaints does not exclude the obstructive mechanism.

Daytime

Nighttime

Frequent micturition

Nocturia

Storage symptom

Nighttime symptom

Slide 53 · Dribbling and dysuria add clinical burden

Overflow dribbling may appear with incomplete voiding.

Dysuria means painful micturition.

Painful urination also prompts attention to possible associated infection.

Obstruction / residual urine

Overflow dribbling

Dysuria and possible infection

Slide 54 · Acute urinary retention is an emergency

Sudden inability to void can complicate BPH.

Urgent catheterization may be required for relief.

This acute event differs clinically from gradually progressive lower urinary symptoms.

Acute inability to void?

Urgent decompression may be required

Assess other symptom mechanisms

Slide 55 · Clinical pathway from nodule to complication

Transition-zone enlargement compresses the outlet.

Bladder compensatory changes and residual urine follow impaired emptying.

Urinary infection or abrupt retention may be clinically important outcomes.

Nodular growth + smooth-muscle tone

Increased urinary outflow resistance

Residual urine / bladder changes

Infection risk or acute retention

Slide 56 · Medical therapy targets two distinct mechanisms

α₁-adrenergic blockade reduces smooth-muscle tone.

5α-reductase inhibition lowers DHT synthesis and can reduce gland size.

The treatments correspond to dynamic versus tissue-growth components.

α₁-blockade

5α-reductase inhibition

Reduces muscle tone

Reduces DHT generation

Dynamic resistance component

Enlarged tissue component

Slide 57 · α₁-adrenergic blockers relax prostatic smooth muscle

Inhibition of α₁-adrenergic receptors as the mechanism.

Less contraction reduces the dynamic contribution to outlet resistance.

This treatment does not depend on directly removing a nodule.

α₁-receptor inhibition

Reduced prostatic smooth-muscle tone

Lower dynamic outlet resistance

Slide 58 · 5α-reductase inhibitors target androgen supply

Inhibiting 5α-reductase reduces testosterone-to-DHT conversion.

Reduced DHT signaling is associated with physical prostate shrinkage.

The effect addresses the hormonal growth component rather than smooth-muscle tone alone.

5α-reductase inhibition

Decreased prostatic DHT production

Prostate-size reduction

Slide 59 · Why combination mechanisms are conceptually complementary

Mechanical tissue bulk and contractile tone both impair urine flow.

α₁-blockers address tone; 5α-reductase inhibitors address DHT-related mass.

This diagram explains therapeutic targets; It is not a comparative efficacy trial.

Bladder outlet resistance

Dynamic: α₁-mediated tone

Static: Nodular tissue bulk

Two distinct drug targets

Slide 60 · Persistent moderate-to-severe disease may need procedures

Procedural options for cases resistant to medical therapy.

Transurethral resection of the prostate (TURP) was long regarded as the gold standard.

The source also lists several alternative tissue-reducing modalities.

Persistent symptoms despite medication

Consider tissue-directed procedure

Restore functional outflow

Slide 61 · Procedural modalities listed

TURP removes obstructing tissue transurethrally.

Other listed approaches use focused ultrasound, laser, heat, vaporization, or radiofrequency.

Choice and comparative outcomes require sources beyond this textbook excerpt.

TURP

HIFU

Laser treatment

Hyperthermia

Electrovaporization

Radiofrequency ablation

Procedures listed; No comparative outcome claims

Slide 62 · Case: Progressive lower urinary symptoms

Hypothetical: An older man develops hesitancy, nocturia, and overflow dribbling.

Explain how nodular enlargement and smooth-muscle tone contribute separately.

Predict what bladder change and infection risk follow incomplete emptying.

Transition-zone nodule

Outlet compression + tone

Residual urine and altered bladder wall

Slide 63 · Case interpretation: Structure to function

Hesitancy reflects resistance at the prostatic outlet.

Nocturia and dribbling fit the symptom cluster in the BPH passage.

Retention creates residual urine, which predisposes to bacterial infection.

Obstructed outlet

Incomplete voiding

Residual urine

Secondary complications

Slide 64 · Morphology exercise: Name the components

Hypothetical TURP chips show variably sized glands amid bland spindle-cell stroma.

What two layers should be sought lining benign glands?

What luminal architectural feature may be present in secretory cells?

Luminal space

Secretory epithelium

Basal layer

Schematic glands; Diagnostic features require genuine H&E review

Slide 65 · Morphology answer: Layered glands with folds

Benign gland lining comprises secretory columnar and basal cuboidal/flattened layers.

Papillary infoldings of secretory epithelium may be present.

The stromal background is an integral part of the hyperplastic process.

Luminal space

Secretory epithelium

Basal layer

Schematic glands; Diagnostic features require genuine H&E review

Slide 66 · Five concepts that organize BPH

The pathology is benign nodular glandular and stromal hyperplasia.

DHT/AR signaling and estrogen-related influences alter tissue turnover.

Transition-zone growth and muscle contraction obstruct the outlet.

Morphologic and clinical consequences determine the principal treatment targets.

Slide 67 · Reference and image-source note

Primary source: Robbins, Cotran & Kumar, Pathologic Basis of Disease, 11th ed. (2026), Chapter 21, pages 887–889.

Source figures 21.27–21.30 were described in the text extraction but not reproduced.

All diagrams in this lecture are original, editable conceptual schematics; no synthetic microscopy is presented as observed evidence.